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Abstract
Background: Inhaled corticosteroids (ICSs) are currently used to prevent and treat asthma and recurrent wheezing
attacks in children. Fluticasone propionate (FP) is one of the most commonly prescribed ICSs because it is considered
effective and well tolerated.
Case presentation: A male infant of approximately 1 year of age, who was born to parents without relevant
clinical problems or family histories including diabetes, was brought to our attention for recurrent wheezing.
When he was approximately 2 years old, a regular daily inhaled treatment with FP given using a spacer was
prescribed. With this therapy, the child obtained good control of his symptoms with no further recurrences, but
after approximately 2 months of treatment he was admitted to the emergency room because he was whining
and agitated and exhibited increased diuresis and water intake. Laboratory tests revealed hyperglycaemia
(181 mg/dL), mild glycosuria, blood alkalosis (pH 7.49), a bicarbonate level of 31 mmol/L, a pCO2 level of
39 mmHg, a serum sodium level of 135 mEq/L and a serum potassium level of 3.5 mEq/L. The parents confirmed
that the recommended dose of FP had been administered with no increase in the amount of drug. The child was
immediately treated with endovenous infusion of physiological saline for 24 h, and his glycaemic levels as well as
venous blood gas analysis returned to normal, with an absence of glucose in the urine. Oral glucose tolerance
test results and glycated haemoglobin levels were normal. Monitoring of blood glucose levels before and after
meals for three consecutive days did not reveal any further increase above normal levels. He was discharged with
a diagnosis of transient symptomatic hyperglycaemia during ICS therapy and the suggestion to replace his
inhaled FP therapy with oral montelukast. Montelukast was continued for 6 months; during this time, the child
did not present any other hyperglycaemia episodes.
Conclusions: Although there is no evidence of causation, this case report represents an interesting and unusual
description of paediatric transient symptomatic hyperglycaemia after treatment with inhaled FP and highlights
the importance of considering this potential adverse event and the necessity of informing parents of the possible
clinically relevant risks associated with this drug.
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Background
As in adults, inhaled corticosteroids (ICSs) are currently
used in children to prevent and treat asthma and recur-
rent wheezing attacks. Fluticasone propionate (FP), ei-
ther alone or in association with other bronchodilators,
is one of the most commonly prescribed ICSs because it
is considered effective and well tolerated [1]. Due to its
low systemic bioavailability, FP has been associated with
a lower rate of adverse reactions in comparison to other
ICSs including budesonide [2]. Moreover, at the recom-
mended doses of 100–200 μg/day FP administration can
significantly reduce the incidence of wheezing exacerba-
tion and improve respiratory symptoms during acute at-
tack without any relevant adverse effects even in young
children [1]. Only long-term treatment with significantly
higher than recommended dosages has been associated
with clinical complications, including growth retard-
ation, bone osteoporosis, and acute adrenal crisis with
hypoglycaemia [3, 4]. Moreover, although a number of
studies have reported that adults receiving ICS, including
FP, can develop diabetes or experience the progression of
already diagnosed diabetes [5], no case of symptomatic
hyperglycaemia has been reported in children (Table 1).
Recently, we diagnosed the first known case of transient
symptomatic hyperglycaemia in a child with recurrent
wheezing and no predisposing factor for poor glucose tol-
erance who was treated with FP. We report this case to
highlight the importance of considering this potential ad-
verse event during FP treatment in children.
Case presentation
A male infant of approximately 1 year of age, who was
born to parents without relevant clinical problems or
family histories including diabetes, was brought to the
Outpatient Clinic for Pediatric Infectious Diseases of the
University of Milan, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy, for recur-
rent wheezing. Staring from the age of 6 months, he had
suffered from monthly episodes of upper respiratory in-
fection associated with severe wheezing at every occa-
sion. At admission, his general condition was good, and
there were no signs or symptoms of infection or bron-
chial obstruction.
Laboratory tests revealed increased IgE levels (124
KU/L), and skin prick testing for standard food and in-
haled allergens was negative. Serum immunoglobulins
(Ig and IgG subclasses) were within normal ranges. On
the basis of the patient’s clinical history, in case of an
acute event, the administration of 100 μg of inhaled FP
administered using a spacer twice a day for 7 days and
then 50 μg twice a week for 3 days was suggested, with
inhaled salbutamol as needed. However, despite this
protocol, over the following 12 months the child experi-
enced 6 additional episodes of wheezing, 3 of which
were severe enough to require oral corticosteroid admin-
istration to be controlled. Consequently, at the begin-
ning of the following fall season (i.e., 6 months after the
last administration of oral corticosteroids), when he was
approximately 2 years old, a regular daily inhaled treat-
ment with FP given using a spacer was prescribed. He
received 100 μg of inhaled FP twice a day starting on
October 1, 2014, and the indication was to continue this
treatment up until February 28, 2015.
With this therapy, the child obtained good control of
his symptoms with no further recurrences, but after ap-
proximately 2 months of treatment he was admitted to
the emergency room because he was whining and agi-
tated and exhibited increased diuresis and water intake.
Table 1 Main characteristics of a child who developed transient
symptomatic hyperglycaemia during treatment with a moderate
dose of inhaled fluticasone propionate (FP)
Characteristic Patient
Age 2 years
Gender Male
Previous personal history Recurrent asthmatic bronchitis and atopic
dermatitis
Familial history Father with allergic asthma induced by
inhaled allergens, uncle with coeliac disease,
no other history of immune-mediated disease
in the family
Allergic tests IgE levels of 124 KU/L, skin prick testing
negative for standard food and inhaled
allergens
Therapies in the past year Repeated courses of 100 μg inhaled FP
twice a day for 7 days and then 50 μg twice
a week for 3 days during acute events; oral
corticosteroids in three cases
Therapy at
hyperglycaemia onset
100 μg inhaled FP twice a day from October
1, 2014, to November 27, 2014
Symptoms at emergency
room admission
Whining and agitation with increased
diuresis and water intake
Clinical signs at
admission
Whining and agitation, no sign suggestive of
acute infection, normal respiratory evaluation
Laboratory evaluation
Glycaemia 181 mg/dL
Glycosuria Present
Blood gas analysis pH 7.49, bicarbonates 31 mmol/L, pCO2
39 mmHg, sodium 135 mEq/L, potassium of
3.5 mEq/L
Oral glucose tolerance
test
Normal
Glycated haemoglobin 7 %
Treatment Endovenous infusion of physiological saline
for 48 h
Persistence of symptoms 6 h
Outcome Replacement of inhaled FP therapy with oral
4 mg montelukast once a day, no further
hyperglycaemia episodes after 6 months
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Laboratory tests revealed hyperglycaemia (181 mg/dL),
mild glycosuria, blood alkalosis (pH 7.49), a bicarbonate
level of 31 mmol/L, a pCO2 level of 39 mmHg, a serum
sodium level of 135 mEq/L and a serum potassium level
of 3.5 mEq/L. The parents confirmed that the recom-
mended dose of FP had been administered with no in-
crease in the amount of drug. The child was immediately
treated with endovenous infusion of physiological saline
for 24 h, and his glycaemic levels as well as venous blood
gas analysis returned to normal, with an absence of glu-
cose in the urine. Oral glucose tolerance test (OGTT) re-
sults were normal and glycated haemoglobin (HbA1c)
level was 7 %. Monitoring of blood glucose levels before
and after meals for three consecutive days did not reveal
any further increase above normal levels. He was dis-
charged with a diagnosis of transient symptomatic hyper-
glycaemia during ICS therapy and the suggestion to
replace his inhaled FP therapy with 4 mg oral montelukast
once a day. Montelukast was continued for 6 months;
during this time, the child did not present any other
hyperglycaemia episodes.
Conclusions
Because of their topical application, ICSs have a substan-
tially better therapeutic index than oral corticosteroids
and have almost entirely replaced these drugs in the pre-
vention and treatment of asthma and wheezing in both
children and adults [1, 5]. FP pharmacokinetic characteris-
tics suggest a very low risk of systemic adverse events [1].
In normal subjects, FP bioavailability is limited to approxi-
mately 1 %, the lowest value among all of the commonly
used ICSs, and its high first-pass metabolism ensures a
prompt inactivation of the amount of drug that is swal-
lowed during administration. Practically, the risk of sys-
temic adverse events with doses useful to control
bronchial obstruction is marginal and is probably even
lower in patients with moderate or severe asthma, in
whom factors such as airflow obstruction and ventilation-
perfusion mismatch could alter drug deposition in the
lung and change systemic absorption. Previous studies on
ICSs efficacy have also included evaluation of their safety
with routine blood chemistry assessment and haemato-
logical testing (that include blood glucose levels), showing
that doses used for wheezing prevention (including FP at
200 μg/day) have no clinically relevant side effects in
pediatric age [6–8]. In children, problems regarding glu-
cose metabolism have been reported only when signifi-
cantly higher than recommended FP doses were used.
Todd et al. have described three children ranging in age
from 7 to 9 years old who received inhaled FP at a dosage
of 500–2000 μg/day for between 5 months and 5 years
and who were admitted to the hospital for seizures sec-
ondary to severe hypoglycaemia (blood glucose between
23.4 and 32.4 mg/dL) [3]. A similar finding has been
reported by Drake et al. in four children treated with FP at
a dose of 500–1500 μg/day for between 15 months and
5 years [4]. In all cases, hypoglycaemia was a consequence
of iatrogenic adrenal suppression [3, 4].
Increased blood glucose concentration is a common
complication of oral corticosteroid administration be-
cause these drugs increase gluconeogenesis and decrease
glucose uptake in the liver and adipocytes by decreasing
insulin binding [9]. In adults, ICS administration has
been associated with a moderate risk of increased blood
glucose concentrations only when administered at higher
than recommended doses or when administered to pa-
tients already diagnosed as diabetic [9]. The child in the
current report had no predisposing factor for poor glu-
cose tolerance, as evidenced by normal values of OGTT
and HbA1c, which were assessed within a few days after
hospital admission. The development of symptomatic
hyperglycaemia is surprising and difficult to explain. The
patient did not receive oral corticosteroids close to the
administration of FP. Due to the presence of glycosuria,
blood alkalosis and clinical symptoms, the hypothesis is
that in the month prior to admission his blood glucose
levels were even higher than those detected by us at ad-
mission in the Emergency Room. However, we did not
evaluate blood glucose and HbA1c concentrations prior
to the initiation of FP and we did not know whether
these values were in the higher normal range before the
beginning of FP treatment. Moreover, FP was prescribed
at an adequate dose and it was administered for a rela-
tively short period of time. The parents confirmed that
FP was administered according to recommendations,
but the reported level of compliance of parents has a
very low accuracy. However, although there is no evidence
of causation, this interesting and unusual case report high-
lights the importance of informing parents of the possible
clinically relevant risks associated with the use of this
drug.
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